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Cardiovascular diseases (CVDs) remain the leading cause of death in the world
and in most developed countries. Patients with type 2 diabetes mellitus (T2DM)
suffer from both microvascular and macrovascular diseases and therefore have
higher rates of morbidity and mortality compared to those without T2DM. If
current trends continue, the Center for Disease Control and Prevention estimates
that 1 in 3 Americans will have T2DM by year 2050. As a consequence of the
controversy surrounding rosiglitazone and the increasing prevalence of diabetes
and CVDs, in 2008 the Food and Drug Administration (FDA) established new
expectations for the evaluation of new antidiabetic agents, advising for pre and,
in some cases, post-marketing data on major cardiovascular events. As a direct
consequence, there has been a paradigm shift in new antidiabetic agents that has
given birth to the recently published American Diabetes Association/European
Association for the Study of Diabetes consensus statement recommending
sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon like peptide-1
receptor agonists (GLP-1RA) in patients with T2DM and established CVD. As a
result of over a decade of randomized placebo controlled cardiovascular outcome
trials, the aforementioned drugs have received FDA approval for risk reduction
of cardiovascular (CV) events in patients with T2DM and established CV disease.
SGLT2i have been shown to have a stronger benefit in patients with congestive
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heart failure and diabetic kidney disease when compared to their GLP-1RA
counterparts. These benefits are not withstanding additional considerations such
as cost and the multiple FDA Black Box warnings. This topic is currently an
emerging research area and this mini-review paper examines the role of these
two novel classes of drugs in patients with T2DM with both confirmed, and at
risk for, CVD.
Key words: Type 2 diabetes mellitus; Glucagon-like-peptide 1 agonists; Sodium-glucose
cotransporter-2 inhibitor; Cardiovascular disease; Major adverse cardiovascular event
©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
Core tip: Cardiovascular diseases are of significant concern in patients with type 2
diabetes mellitus. Novel therapies offer a new opportunity for cardiovascular risk
reduction and add complexity in terms of selecting antihyperglycemic treatment. These
pharmacological therapies, however, also have additional considerations.
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Cardiovascular disease (CVD) is the most important cause of morbidity and mortality
in patients with type 2 diabetes mellitus (T2DM), with approximately 20% of the
individuals with this condition suffering from established atherosclerotic disease[1-4].
The cardiovascular (CV) risk seems to be driven largely by coexisting conditions in
addition to the independent risk related to hyperglycemia[5].
Modern medicine uses a polypharmacy approach due to the nature of the disease.
Lipid  lowering  agents  have  been  studied  for  years  and  data  supports  their
cardiovascular benefit in selected patient with and without T2DM[6]. Antithrombotic
therapies for primary and secondary prevention are a topic of much debate in recent
years,  with data both supporting[7],  and refuting[8]  the idea of  one-size-fits-all  in
patients with T2DM. Blood-pressure goals have also been a point of controversy, as
demonstrated by Effects of Intensive Blood-pressure Control in T2DM trial [by the
Action to Control Cardiovascular Risk in Diabetes (ACCORD) study group][9] and by
the variation of goal blood pressures in major guidelines.
Intensive versus standard glycemic control has been a research question dating
back to the 1990s with the United Kingdom Prospective Diabetes Study[10] with 3867
patients with T2DM and the Diabetes Control and Complications Trial[11] with 1441
patients with type 1 diabetes mellitus (T1DM). These trials demonstrated reduced
microvascular endpoints but no difference in macrovascular endpoints with intensive
glycemic control.  Metformin use was associated with a reduction in DM-related
complications and all-cause mortality. Fast-forward to 2008-09 and we have the large
Action in Diabetes and Vascular Disease ADVANCE[12] trial with 11140 patients and
the Veterans Affairs Diabetes Trial[13]  with 1,791 patients, both showing intensive
glycemic  control  having no impact  on macrovascular  outcomes in  patients  with
T2DM.
Given the heterogeneity of diabetes, caution must be had in extrapolating results of
one trial to a population with different baseline characteristics, whether that be the
type  of  diabetes  or  the  CVD  risk.  For  example,  the  Epidemiology  of  Diabetes
Interventions and Complications trial in 2005[14] showed that patients with T1DM had
diminished  rates  of  CVD  with  more  stringent  HbA1C  targets.  Then  the  same
intervention of stringent HbA1C target resulted in the opposite outcome in those with
T2DM in the  large  ACCORD trial  in  2008[15]  with  10251 patients,  demonstrating
increased mortality and no CV benefit.
With hypoglycemia identified as a driving factor for the increased rate of CV events
and related mortality[16], our HbA1c targets became more liberal with many guidelines
recommending  HbA1c  of  7%.  As  a  result  of  the  perceived  need  to  avoid  hypo-
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glycemia, a new drug class, the dipeptidyl peptidase-4 inhibitors, became available in
the United States in 2007. They have shown non-inferiority in atherosclerotic CVD,
yet, saxagliptin in particular has shown a potential risk in congestive heart failure. For
the purposes of this mini-review, this class will not be covered in detail as there are no
studies  showing superiority  in  preventing major  cardiovascular  events  (MACE)
(Table 1).
One  provocative  event  was  when  Rosiglitazone  had  a  post-marketing  meta-
analysis  showing  an  increased  risk  of  CV  events  in  T2DM  patients  using  this
medication. With that debacle and the increasing prevalence of T2DM and CVDs, in
2008 the Food and Drug Administration (FDA) issued new mandates on MACE safety
for new antidiabetic drugs. Studies had to be presented prior to approvals and these
would be followed by post-marketing cardiovascular outcome trials (CVOTs). This
decision has helped bring data that, otherwise, would not have been available.
The paradigm shift has been to have antihyperglycemic agents show, not only
noninferiority, but superiority in reducing MACE. As a result of over a decade of
randomized placebo controlled CVOT,  drugs  in  two classes  have  received FDA
approval for risk reduction of CV events in patients with T2DM and established CV
disease;  glucagon like  peptide  receptor  agonists  (GLP1RA) and sodium-glucose
cotransporter-2 inhibitors (SGLT2i).
The decision for clinicians in selecting a second antihyperglycemic agent after
metformin in T2DM has become significantly more complex with much more data to
consider (Tables 2 and 3). We will review the pharmacology followed by the current
evidence  of  cardiovascular,  renal,  blood  pressure,  weight  and  other  effects  of
GLP1RAs and SGLT2is.
PHARMACOLOGY
Glucagon like peptide-1 receptor agonists (GLP-1RAs) have been available in the
market since 2005, however it has taken over a decade to understand their effects. As
an endogenous substance, its insulinotropic effect when associated with glucose-
dependent insulinotropic polypeptide is  very well  established, giving rise to the
incretin effect[17] (Figure 1), which is significantly reduced in T2DM. Moreover, the
discovery of  receptors  in  the  periphery[18]  sensitive  to  GLP1 have raised several
questions regarding the reach in which our exogenous, man-made GLP-1RA can have
a positive impact in the health of patients with T2DM[19] given their increased potency
and half-life compared to endogenous GLP1.
SGLT2 inhibitors have been available in our armamentarium since 2012 and were
first used unrelated to β-cell  function and insulin sensitivity[20].  Originating from
observations and studies made on patients with Familial Renal Glucosuria[21],  the
effects of inhibiting SGLT2 are still under thorough investigation given the presence
of such molecules not only in the proximal tubule of the nephron, but also on the
glomerular basement membrane and in the heart[22].
CURRENT EVIDENCE
Cardiovascular effects
Agents in both GLP-1RA and SGLT2i classes have obtained approval by the FDA for
the indication of CV risk reduction in patients with T2DM and established CVD.
Current data has proven that these agents can reduce the risk of MACE (CV death,
nonfatal myocardial infarction and nonfatal stroke) with questions remaining on the
ideal level of cardiovascular risk to benefit from GLP1RA. The CVOT design was
intended  to  have  both  treatment  groups  maintain  similar  glycemic  control,  to
minimize  this  confounder.  In  addition  to  this,  SGLT2i  have  shown evidence  of
reduced hospitalization due to heart failure. New submissions to the FDA for both
drug classes are in process.
The first GLP-1RA CVOT was the Evaluation of Lixisenatide in acute coronary
syndrome trial[23] in 2015, studying the effects of lixisenatide in a high risk population
with subjects that had an acute coronary syndrome in the 6 mo prior to the study with
an average starting HbA1c of 7.7%, demonstrating noninferiority when compared to
placebo but no superiority. One of the limitations of the trial was its short duration
and the severity of the illness in this very high-risk population.
In 2016, GLP-1RA gained much more attention after the Liraglutide Effect and
Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER)[24] trial
demonstrated the superiority of liraglutide in the primary end point (PEP) when
compared against placebo in subjects with T2DM and high risk for CV events. These
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Table 1  Summary of dipeptidyl peptidase 4 cardiovascular outcome trials
Trial NumberFollow up CVD (baseline) Characteristics(baseline)




n = 16492, 2.1 yr
(median)
Pre-existing CV or high
CV risk/multiple CV
risk factors
65 y/o, DM duration: 10
yr; A1c: 8%; BMI: 31
7.3 vs 7.2 No
EXAMINE (Alogliptin)
2013
n = 5380, 1.5 yr (median) Acute MI or HUA in
previous 15 to 90 d
61 y/o, DM duration: 7
yr; A1c: 8%; BMI: 29
11.3 vs 11.8 No
TECOS (Sitagliptin)
2015





65.5 y.o, DM duration:
11.6 yr; A1c: 7.2%; BMI:
30.2
11.4 vs 11.6 (4-point
MACE)
No
Note, as a class dipeptidyl peptidase 4 inhibitor has no data for significant reduction in cardiovascular endpoints. The TECOS trial had a 4-point MACE,
consisting of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke or hospitalization for unstable angina. DPP4: Dipeptidyl
peptidase 4; CVOT: Cardiovascular outcome trial; CVD: Cardiovascular disease; PEP: Primary end point; BMI: Body mass index; HUA: Hospitalization
due to unstable angina; MI: Myocardial infarctions; PAD: Peripheral artery disease; CAD: Coronary artery disease; MACE: Major cardiovascular events.
patients  had a lower rate of  CV death,  nonfatal  myocardial  infarctions (MI)  and
nonfatal strokes (but no statistical difference with all strokes). Starting average HbA1c
was  8.7%.  The  rate  of  hospitalization  due  to  heart  failure  remained statistically
nonsignificant.
Also, in 2016, the Trial to Evaluate Cardiovascular and Other Long-term Outcomes
With Semaglutide in Subjects With Type 2 Diabetes (SUSTAIN-6)[25] compared the
once-weekly  injection  of  semaglutide  to  placebo  and  had  similar  outcomes  to
liraglutide  on a  patient  with  a  sizable  prevalence  of  ischemic  heart  disease  and
hypertension (60% and 93% respectively). This was achieved with fewer patients and
less years of  follow-up (2 compared to 4 in the LEADER trial).  The once-weekly
injection of semaglutide was FDA approved in 2017 and in 2019 Novo Nordisk filed
for  FDA  approval  for  a  new  CV  indication  based  on  the  SUSTAIN-6  trial.
Simultaneously they filed for FDA approval for oral semaglutide[26] which would be
the first GLP1RA in a pill form and the pertaining CVOT PIONEER6 is discussed
below.
Subsequently  in  2016-2017,  two  CVOTs  were  published  on  another  GLP1RA
exenatide. The Exenatide Study of Cardiovascular Event Lowering Trial[27] confirmed
noninferiority with once weekly subcutaneous injection of exenatide but lacking
superiority when comparing to placebo. The study had the largest population in
CVOT at the time with 14752 patients, from which 70% had a previous CV event,
including coronary artery disease, ischemic cerebrovascular disease or peripheral
artery disease. On average, the starting HbA1c was 8%. The main pitfall of the study
was the inclusion of a sizable number of patients using SGLT2i in the placebo group.
A phase 3 safety trial, FREEDOM-CVO[28], had more than 4,000 patients supplied with
exenatide through a continuous implanted pump and announced non-inferiority in
CV safety.  The  subcutaneous  pump would  potentially  address  the  high  rate  of
discontinuation with weekly exenatide, which was 43%.
Finally,  in  2018,  three  more CVOTs with GLP-1RAs were announced and full
results are yet to be reported. REWIND[29], investigating a weekly dulaglutide with an
international scope, 46% women, and including T2DM with coexisting CVD or 2 or
more CV risk factors. Only 36% of the 9901 patients had established CVD, yet at a
median follow-up of 5 years, dulaglutide was still  showing significantly reduced
MACE. Next,  Albiglutide was studied in the HARMONY[30]  trial  which was also
international  across  28  countries  and  enrolling  9463  participants  but  all  had
established CVD and it  was  superior  to  placebo in  reducing MACE.  Lastly,  the
PIONEER6[31] examined oral semaglutide in patients with T2DM with high risk of CV
events and showed non-inferiority but not superiority in MACE. Secondary outcomes
though showed statistically significant reduction in CV death and all-cause mortality
in those 3183 patients.
SGLT2i also had its first CVOT published in 2015, Empagliflozin, Cardiovascular
Outcomes and Mortality in Type 2 Diabetes trial (EMPA-REG OUTCOME)[32]. They
enrolled 7028 patients with recognized CVD or elevated CV risk with an average
starting HbA1c of 8%, demonstrating superiority over placebo, similar to the PEP of
the LEADER trial with an additional benefit for hospitalization for heart failure and
diabetic nephropathy. Later,  the Canagliflozin Cardiovascular Assessment Study
(CANVAS)[33]  and the Study of the Effects of Canagliflozin on Renal Endpoints in
Adult Participants with T2DM (CANVAS-R) trials had similar results by examining
approximately  10000  patients  with  established  CVD  in  a  younger  population.
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Table 2  Summary of the results of the most important Randomized Controlled Trials prior to the new classes of antidiabetic medications
Study Effects on microvascularcomplications
Effects on macrovascular
complications Effect on total mortality
DCCT[10] (1993), T1DM Reduced retinopathy, nephropathy,
neuropathy




UKPDS[9] (1998) Reduced microvascular endpoints No difference on myocardial
infarctions
No difference
ACCORD[14] (2008) Reduced retinopathy, nephropathy,
neuropathy
No difference on MACE Increased mortality
ADVANCE[11] (2008) Reduced nephropathy No effect on MACE No difference
VADT[12] (2009) Reduced progression of albuminuria No effects on major cardiovascular
events
No difference
Note the lack of difference in macrovascular complications despite reduced microvascular complications, which is consistent among all studies. MACE:
Major adverse cardiovascular events; DCCT: Diabetes Control and Complications Trial; T1DM: Type 1 diabetes mellitus; UKPDS: United Kingdom
Prospective Diabetes Study; ACCORD: Action to Control Cardiovascular Risk in Diabetes; ADVANCE: Action in Diabetes and Vascular Disease: Preterax
and Diamicron MR Controlled Evaluation; VADT: Veterans Affairs Diabetes Trial.
However, the magnitude of the benefit with canagliflozin was smaller compared to
other trials (only a third of 1%, meaning we would have to treat several hundred more
patients to prevent a MACE). It also raised safety concerns by showing increased risk
for lower limb amputations and fractures while also being consistent with previous
CVOTs in regards of the increased risk for mycotic infections but no change in rates of
Diabetic Ketoacidosis.
In 2019, the Dapagliflozin Effect on Cardiovascular Events trial (DECLARE – TIMI
58)[34] studied dapagliflozin for primary and secondary prevention in patients with
T2DM and CVD or at high-risk for CVD and was the largest CVOT to date with 17160
patients.  It  showed noninferiority  in MACE without  superiority.  A reduction in
hospitalization for heart failure and all-cause mortality was established with robust
reductions in the renal composite endpoints, suggesting a delay in the development
and progression of renal disease.
Results have for the most part been consistent, as was demonstrated by Cheng et
al[35], who analyzed a total of 12 double-blind randomized controlled trials, concluding
that liraglutide, empagliflozin and canagliflozin to be superior in CV outcome in
comparison to placebo in patients with T2DM and established or high-risk for CVD.
Renal effects
From  the  abundance  of  evidence,  clinicians  have  already  established  that  the
intensification of  glycemic  control  is  the  best  approach to  reduce microvascular
complications. But when microvascular disease has already taken place, our options
have  remained limited,  with  our  first  line  of  defense  consisting  of  angiotensin-
converting enzyme inhibitors or angiotensin-receptor blockers (ARB) in the case of
nephropathy and blood pressure control, and symptomatic treatment for the case of
neuropathy and retinopathy.
Most of the large RCTs involving either SGLT2i or GLP-1RA have demonstrated, to
varying degrees, a reduction in microvascular endpoints and associated morbidity.
This is especially relevant for patients with chronic kidney disease and albuminuria,
who represent a vulnerable subset of patients who, until recently, lacked treatment
options  for  both preventing the  development  of  the  disease  and delayed the  its
progression when these two factors are already present.
SGLT2i have demonstrated effects in hyperglycemic states by enhancement of
glycosuria  and  natriuresis[36].  These  effects  may  have  a  renal  protective  role  by
indirectly lowering blood pressure by competitively blockading the SGLT2 receptors
in the proximal convoluted tubules in the kidneys, thus preventing reabsorption of
the filtered glucose and sodium, decreasing the overall effective intravascular volume
in addition to the intended antihyperglycemic effect.
This is further exemplified by a new prospective analysis by Sugiyama et al[37]. In
this study, dapagliflozin was used in patients with T2DM with ineffective glycemic
control. Those patients who were treated with dapagliflozin had a significant decrease
in urine albumin-to-creatinine ratio (UACR) and urine N-acetyl- β-glycosaminidase, a
marker of kidney injury. We can speculate based on these findings that dapagliflozin
might  prevent  the  renal  tubulointerstitial  atrophy  that  is  correlated  with  the
development of chronic kidney disease (CKD) in patients with T2DM.
Patients with early and uncontrolled T2DM have an increased glomerular filtration
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Table 3  Summary of glucagon-like-peptide-1 receptor agonists and sodium glucose cotransporter 2 inhibitors Randomized Controlled
Trials
Trial Number Follow up CV disease (baseline) Characteristics(baseline)




n = 6068, 2.1 yr Acute Coronary Events
(previous 180 d)









n = 9340, 3.8 yr (median) > 50 y/o + > 1 CV
condition/CKD or
Chronic HF or > 60 y/o
> 1 risk factor for CVD




13.0 vs 14.9 Yes
SUSTAIN-6[24]
(Semaglutide) (2016)
n = 3297, 2.1 yr (median) > 50 y/o + > 1 CV
condition/CKD or
Chronic HF or > 60 y/o
> 1 CV condition




6.6 vs 8.9 Yes
EXSCEL[26] (Exenatide)
(2017)
n = 14752, 3.2 yr
(median)








11.4 vs 12.2 No
REWIND
(Dulaglutide) (2019)
? ? ? ? ?
EMPA-REG[31]
(Empagliflozin) (2015)
n = 7020, 3.1 yr (median) Established CV disease;
high CV risk
mean age: 63; DM
duration: > 10 yr 57%; 5-
10 yr 25%; A1c: 8.07%;
BMI: 30.6





Total = 10142; CANVAS:
n = 4330; CANVAS-R n
= 5812; 3.6 yr (mean)
> 30 y/o at high CV risk
(ASCVD) Or > 50 y/o >
2 CV risk factors




9.8 vs 10.1 Yes
DECLARE[33]
(Dapagliflozin) (2019)
n = 17160; 4.2 yr
(median)
> 40 y/o established
CVD or multiple risk
factors




8.8 vs 9.4 No
Not all the molecules currently available in the market have shown benefit for MACE. However, this can be explained by study design and/or random
chance.  More trials are needed to verify such findings.  Note the CANVAS and CANVAS – R trials had to standardize their results to number of
participants/1000 patient-yr. The results depicted in this table were converted to percentage. The REWIND trial results will become available on the ADA
scientific meeting, 2019. The ELIXA trial had 4-point PEP that consisted in death from cardiovascular causes, nonfatal myocardial infarction, nonfatal
stroke or hospitalization for unstable angina. GLP-1 RA: Glucagon-like-peptide-1 receptor agonists; SGLT2i: Sodium glucose cotransporter 2 inhibitors;
PEP: Primary end point; CV: Cardiovascular; MACE: Major cardiovascular events; CKD: Chronic kidney disease; CVD: Cardiovascular disease; HF: Heart
failure;  PAD: Peripheral artery disease;  CAD: Coronary artery disease;  ELIXA: Evaluation of Lixisenatide in acute coronary syndrome; LEADER:
Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results; SUSTAIN-6: Trial to Evaluate Cardiovascular and Other Long-
term Outcomes with Semaglutide in Subjects with Type 2 Diabetes;  EXSCEL: Exenatide Study of Cardiovascular Event Lowering Trial;  REWIND:
Researching cardiovascular Events with a Weekly Incretin in Diabetes; EMPA-REG: Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2
Diabetes trial; CANVAS: Canagliflozin Cardiovascular Assessment Study; CANVAS-R: A Study of the Effects of Canagliflozin on Renal Endpoints in
Adult Participants with Type 2 Diabetes Mellitus; DECLARE: Dapagliflozin Effect on Cardiovascular Events trial.
rate (GFR). This exposes the proximal tubule to insulin and other growth factors,
leading  to  hyperplasia  and  hypertrophy  in  the  tubular  cells  with  significant
hyperfiltration[38]. In turn, hyperfiltration could be the leading cause of renal damage
in people with T2DM. SGLT2i can reverse this hyperfiltration in certain patients by
blocking  the  glucose  reabsorption  in  the  proximal  tubule.  A  model  of  renal
hyperfiltration developed with pharmacokinetics (PBPK) and pharmacodynamics
(PD) by the Quantitative Systems Pharmacology Diabetes Platform have confirmed
this hypothesis[39].
The evidence evaluating renal benefits of SGLT2i until recently, was limited by the
fact that there has been no RCT trial where the primary outcome is renal with SGLT2i
(recently, this has changed, see below). A meta-analysis of the CVOTs of SGLT2i in
patients with T2DM including 34322 patients performed by Zelniker et al[40] in Lancet
2019 concluded that SGLT2i decreased the risk of progression of renal failure by 45%
with lesser reductions in progression of renal disease in patients with more severe
kidney disease at baseline.
Another 2019 systematic review of 27 studies totaling 7363 participants with T2DM
and CKD[41]  found SGLT2is  demonstrated  a  nonsignificant  decline  in  estimated
glomerular filtration rate (eGFR) slope, though a significantly reduced risk of the
composite renal outcome. A retrospective analysis made by Kobayashi et al[42], defined
the renal effects of SGLT2i in Japanese patients with T2DM with CKD. Results were
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Figure 1
Figure 1  Mechanism of action of the sodium glucose cotransporter 2 inhibitors and the glucagon-like-
peptide-1 receptor agonists. Glucagon-like-peptide-1 receptor agonists slows gastric emptying, suppresses
glucagon secretion while also stimulating insulin secretion by inhibiting and stimulating, respectively, Alfa and Beta
cells in the pancreas. This in turn inhibits hepatic gluconeogenesis with subsequent increase in glucose uptake in the
skeletal muscles, diminishing hyperglycemia. Sodium glucose cotransporter 2 inhibitors reduce glucose reabsorption
in the proximal convoluted tubule, inherently enhancing glucosuria. This created a global hypovolemic and
hypocaloric state, which diminishes hyperglycemia. SGLT2: Sodium glucose cotransporter 2; GLP-1: Glucagon-like-
peptide-1.
statistically significant for reduction in the UACR. GLP-1 RA have also demonstrated
a certain degree of  renal  protection.  Liraglutide and semaglutide have shown to
decrease albuminuria while also halting the worsening of the eGFR[43].
GLP-1  acts  directly  in  the  kidney  by  inhibiting  the  NH3-dependent  sodium
reabsorption in the proximal tubule. The renal outcomes were a secondary outcome
assessed in the LEADER trial[23], showing a delay in new onset macroalbuminuria
with  a  reduction  of  26%  in  patients  with  liraglutide  and  a  notable  decrease  in
UACR[44].
Due to lacking studies with primary renal outcomes, no GLP1RAs or SGLT2s have
FDA approval for indication of renal benefits with T2DM. The recently published
Canagliflozin  and  Renal  Endpoints  in  Diabetes  with  Established  Nephropathy
Clinical Evaluation (CREDENCE) trial[45], whose data was published recently, might
be a game changer. It is been almost 18 years since the advent of renin-angiotensin-
aldosterone system blockers, the last advancement in the area. The study randomly
assigned patients to receive canagliflozin or placebo on top of renin-angiotensin-
aldosterone-system (RAAS) blocker therapy, observing an impressive 30% relative
risk  reduction  in  the  primary  endpoint  consisting  of  end-stage  kidney  disease,
doubling of  serum creatinine,  or  renal  or  cardiovascular  death that  seems to  be
independent of the glucose lowering properties due to the minimal A1c difference at
the end of  the study (0.1%).  This  concept will  be tested in the ongoing trials  for
dapagliflozin and empagliflozin (Dapa-CKD and EMPA-KIDNEY trials respectively)
which have a sizable portion of participants without diabetes.
Additionally, it is also important to remember renal dosing requirements. SGLT2i
require, in general, an eGFR greater than 45. For now, dulaglutide and liraglutide
remain as the only novel medications that can be used in moderate to severe CKD
given the evidence provided by the Dulaglutide versus insulin glargine in patients
with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7)
trial[46] and the LEADER trial.
Blood pressure effects
Both SGLT2is and GLP1RA have shown reduction in blood pressure, independent
from their hypoglycemic mechanisms[47]. In Tikkanen’s[48] study of patients with T2DM
and hypertension,  at  week 12  the  mean difference  versus  placebo in  mean 24-h
systolic blood pressure was -3.44 mmHg and -4.16 mmHg with 10 mg and 25 mg of
empagliflozin,  respectively.  Blood pressure can be reduced also in patients with
nocturnal  hypertension,  as  demonstrated in  the  SGLT-2i  and ARB Combination
Therapy  in  Patients  with  T2DM  and  Nocturnal  Hypertension  (SACRA)  study,
conducted in Japan. The reduction in nighttime systolic blood pressure (SBP) with the
use of empagliflozin was associated with daytime reductions in SBP and 24-h SBP[49].
The activation of the RAAS increases the SGLT2 mRNA expression in the proximal
renal tubular epithelial cells with subsequent sodium intake. This causes an expansion
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in the intravascular volume that leads to hypertension[50]. Although the inhibition of
SGLT2 will activate the RAAS, it is suggested to combine the SGLT2i with any RAAS
blockers to suppress RAAS and thus prevent hypertension[51].
Within GLP1RAs,  exenatide and liraglutide have displayed a reduction in the
systolic and diastolic blood pressure from 1 to 5 mmHg in comparison with other
antidiabetic  medications,  like insulin,  glimepiride,  metformin,  or  placebo[52].  Co-
initiating the GLP1RA exenatide and the SGLT2i dapagliflozin compared to either
agent alone, the DURATION-8[53] trial showed the combination lowered the systolic
blood pressure 4.1 mmHg, which was greater than either agent alone. Similar to renal
outcomes,  blood pressure  has  been a  secondary outcome yet  a  beneficial  one in
alleviating some burden of hypertension with an antidiabetic agent[54].
Weight effects
Increasing BMI can lead to the development of T2DM and poses a greater risk of CVD
and  all-cause  mortality.  Weight  loss  in  patients  with  T2DM  is  critical  in  the
improvement of hyperglycemia and cardiovascular comorbidities like hypertension
and hyperlipidemia[55].
Currently, the American Diabetes Association and the European Association for the
Study of Diabetes have made an emphasis in the importance of lifestyle modifications,
diet  and  exercise  in  patients  with  T2DM.  Unfortunately,  many  of  our  antihy-
perglycemic agents are associated with weight gain including thiazolidinediones,
sulfonylureas and insulin. Though modest at 1-3kg weight loss[56], this has made the
SGLT2i and the GLP-1RAs benefits in weight loss even more exciting.
In the DURATION-6[57] trial, extended-release exenatide demonstrated an average
weight loss of about 2.87 kg, and liraglutide[58] has shown to reduce 4 to 6 kg of weight
loss. The SCALE[59] trial evidenced an 8.4 kg weight loss compared to a placebo group
of 2.8 kg when treating patients without T2DM with a high-dose of 3.0 mg injected
liraglutide as an adjunct to diet and exercise. One must keep in mind the CVOT trials
were mostly the 1.8 mg dosing and the applicability of these results to the 3.0 mg dose
is unknown.
Moreover,  in 2017,  semaglutide[23]  was associated with significant weight loss,
which has shown to be superior to liraglutide in its dose for treatment for T2DM.
Even  though  semaglutide  not  been  approved  for  pharmacological  weight  loss
therapy, it opens the possibility for one more GLP-1 RA being used as an anti-obesity
drug that would prevent cardiovascular events in patients with T2DM. SGLT2i are
associated with a more modest reduction of body weight, with dapagliflozin showing
a mean 1.63 kg reduction compared with placebo. The DURATION-8[52] clinical trial
confirmed that a combination of dapagliflozin and exenatide, plus metformin as a
background therapy, resulted in a secondary outcome of weight loss of 3.4 kg, which
was greater than either drug alone. Nevertheless, the trend is that GLP1RAs offer
more weight loss compared to SGLT2i, which is a relief compared to the classes that
are associated with weight gain such as insulin and sulfonylureas.
While these medications are helpful in weight management, it is important to keep
in mind this does not triumph over comprehensive lifestyles changes with aerobic
exercise and dietary changes. Also, equally important, weight loss using GLP-1 RA
should be monitored at least every 3 mo from the starting of the treatment due to side
effects[60].
Additional considerations
Several concerns exist with both GLP-1RAs and SGLT2is which must be weighed
against  the benefits  detailed above.  Like with any agent,  discussion of  risks and
benefits when starting treatment is recommended. GLP-1RAs most common adverse
effect is gastrointestinal with nausea, vomiting and diarrhea[61]. Commonly, nausea
tends  to  wane  over  time.  Patients  should  be  informed about  this  as  well  as  the
possibility of injection site reactions when beginning therapy. An increased rate of
acute and/or chronic pancreatitis has been established with the available RCTs, but
there is no firm evidence pointing towards causality[62]. Preclinical data from studies
done in rodents[63]  raised the possibility of  a  medication induced carcinogenesis,
specifically medullary thyroid cancer (MTC), however, these effects may be irrelevant
in humans[64]. Nevertheless, a Black Box warning remains with GLP1RAs and risk of
thyroid c-cell tumors, including a contraindication in patients with personal or family
history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2.
SGLT2is most common adverse effect is genitourinary. There is a fivefold increased
risk of genital fungal infections with SGLT2i, including an FDA warning about rare
occurrences of Fournier’s gangrene[65]. Multiple RCTs show increased risk of bacterial
urinary  tract  infection  versus  placebo,  which  can prove  to  be  a  challenge  when
considering  treatment[66].  No  clinical  trial  has  examined  special  circumstances
(indwelling  bladder  catheterization,  benign  prostatic  hypertrophy,  chronic
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obstruction or ureteral  reflux) but caution under these circumstances is  advised.
Given the inherent diuretic effect, patients who are prone to volume depletion (use of
loop  diuretics,  the  elderly)  are  at  increased  risk  of  complications,  including
hypotension[67].
The FDA[68]  has issued a warning regarding SGLT2i users being more prone to
DKA, secondary to the intrinsic shift in the metabolism of glucose to fat oxidation
with the promotion of hyperglucagonemia and ketosis[69].  Canagliflozin has been
associated with an increased risk for  fractures[70]  and lower-limb amputations[32],
including a Black Box warning for the amputation risk. There is need for further
research on whether these side effects are a class effect or unique to canagliflozin.
One of the most controversial topics is the cost-effectiveness and the prohibitive
out-of-pocket costs of both drug classes. Studies with reliable results on the long-term
economic burden are scarce. The number needed to treat on both classes is in the
hundreds  based  on  the  CVOTs  from  which  the  indication  for  cardiovascular
prevention was approved by the FDA. GLP-1RAs demonstrated CV benefit  after
several years of median follow up, compared to SGLT2is, specifically empagliflozin,
which demonstrated a divergence in survival curve for MACE at 3 mo in the EMPA-
REG study. Some of the drugs that had a statistically significant benefit in the PEP for
cardiovascular outcome had a very small percentage of benefit over placebo (i.e.,
canagliflozin  with  0.3%  benefit  over  placebo).  Side  effects  like  lower-limb
amputations, DKA and pancreatitis can be economically damaging and add several
thousand dollars to the already high economic burden.
CONCLUSION
In summary, given the current data, both GLP-1 RA and SGLT2i have, to varying
degrees, a benefit in renal and cardiovascular protection independent of their glucose-
lowering potential in patients with T2DM and high risk of CVD. Additionally, they
have more modest benefits in blood pressure and weight control. The low risk for
hypoglycemia is appealing.
When starting therapy, the cost-effectiveness is a concern shared by clinicians and
patients. The number needed to treat to prevent MACE in both drug classes are in the
hundreds and the economic burden is in the thousands to millions per patient per
year. Considering the benefits in each study were observed after several years of
follow up, the out-of-pocket expense could be prohibitively high.
Both common and rare adverse effects are also a consideration. SGLT2i carry an
increased  risk  for  mycotic  urinary  tract  infections,  dehydration  and  DKA.
Canagliflozin  additionally  has  the  concerns  of  bone  fractures  and  lower-limb
amputations.  GLP-1RAs  have  been  associated  with  both  acute  and  chronic
pancreatitis, as well as a common side effect of nausea. The evidence for pancreatitis
is debatable and weak since it is not supported by trials or a meta-analysis. Reports of
increased MTC risk in rodents has the resultant black box warning of thyroid c-cell
tumors. Specific trials designed to take a closer look at these effects will be necessary
in the future to prepare a better risk-benefit assessment. The economic burden needs
to be added to the equation.
As more studies concerning different agents on the same class of drugs are added
to the already existing data, the question on whether each new finding is a class affect
or a molecule-based outcome will be determined. With the current evidence at our
disposal, we cannot guarantee that GLP-1 RAs all have the same benefits and what
the ideal patient population is to maximize those benefits. SGLT2is, on the other hand,
seem to offer a more homogenous effect with certain differences that can be attributed
to each individual study to a certain extent, but more research is necessary.
As clinicians, we are moving a step forward in T2DM management. Now, patients
can be offered antihyperglycemic agents that will  treat micro and macrovascular
complications while also treating independent risk factors, maintaining an acceptable
level of antihyperglycemic effect with a low risk for hypoglycemic events.
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